Five Prime Therapeutics (FPRX) & Its Peers Critical Comparison
Five Prime Therapeutics (NASDAQ: FPRX) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Five Prime Therapeutics to similar businesses based on the strength of its risk, dividends, valuation, earnings, analyst recommendations, profitability and institutional ownership.
Volatility & Risk
Five Prime Therapeutics has a beta of 4.16, suggesting that its share price is 316% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics’ peers have a beta of 6.57, suggesting that their average share price is 557% more volatile than the S&P 500.
Valuation & Earnings
This table compares Five Prime Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Five Prime Therapeutics||$32.90 million||-$133.09 million||-8.43|
|Five Prime Therapeutics Competitors||$464.94 million||$167.77 million||-6.74|
Five Prime Therapeutics’ peers have higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
84.1% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 6.5% of Five Prime Therapeutics shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for Five Prime Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Five Prime Therapeutics||0||0||7||0||3.00|
|Five Prime Therapeutics Competitors||1382||4481||12322||313||2.63|
Five Prime Therapeutics presently has a consensus price target of $61.20, indicating a potential upside of 71.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.29%. Given Five Prime Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Five Prime Therapeutics is more favorable than its peers.
This table compares Five Prime Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Five Prime Therapeutics||-356.39%||-31.78%||-27.55%|
|Five Prime Therapeutics Competitors||-4,765.58%||-354.90%||-43.38%|
Five Prime Therapeutics beats its peers on 7 of the 12 factors compared.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.